In summary, 5-Aza-2’ and TAK981 have potential to synergistically inhibit tumor cell growth and UBC9 and DNMT1 expression could be potential biomarkers for sensitivity of lymphomas for the combination therapy. Here, DNMT1 is linked to neoplasm.